MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D.
“We are excited to have Grégoire join our executive team at this pivotal moment for MRM Health, on the cusp of late-stage clinical development for our lead candidate MH002 in ulcerative colitis and pouchitis, from our proprietary CORAL platform designed to harness the full power of the gut microbiome to develop effective and safe therapeutics,” said Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health. “Grégoire’s extensive expertise in corporate development, combined with his strategic acumen, will be crucial as we continue to advance our pipeline and expand our reach.”
Mr. Franoux will lead the company’s business development and corporate strategy, focusing on forging strategic partnerships and driving growth. He brings 20 years of experience in strategic planning, licensing, business development and corporate finance within the biotechnology sector. He joins MRM Health from Belfius Bank, where he was spearheading Corporate Finance and Capital Markets activities in the Life Sciences sector. Prior to joining Belfius, Gregoire held senior business development positions at Oxurion, Gruenenthal GmbH and Flamel Technologies. He holds an M.S. in Biotechnology from ESIEE Paris, an M.S. in International Finance from IAE Aix-Marseille, and an Executive M.B.A. from INSEAD.
“It is an exciting time to join the MRM Health team as the company makes important progress advancing next-generation LBPs for inflammatory, CNS and metabolic diseases. I look forward to optimizing the value of MRM’s potentially life-altering therapies and delivering them to patients in need,” commented Grégoire Franoux.
In addition, MRM Health welcomes Ron Robison, M.D., to its Board of Directors. Ron, who previously served as Vice President at AbbVie, brings over three decades of experience in drug development and commercialization. Ron also served in global senior pharmaceutical R&D leadership roles at several organizations, including Mallinckrodt Medical, Sanofi/Sterling Winthrop, Nycomed, Amersham Health, Abbott and Head of R&D and Chief Medical Officer at Solvay Pharmaceuticals. Ron has overseen the approval of more than 20 new molecular entities worldwide with over ten innovative clinical indications obtained under FDA breakthrough therapy designation. Dr. Robison holds an M.D. from the Oregon Health Sciences University, an M.S. in Medical Informatics/Biomedical Engineering from the University of Utah, and a B.S. from Oregon State University.
MRM Health Chairman Werner Cautreels added, “We are thrilled to have Ron join our Board. His deep industry knowledge and experience progressing assets through clinical and global regulatory development will be invaluable as we continue to grow and develop potentially transformative therapies.”
-Ends-
About MRM Health
MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical development in Ulcerative Colitis and/or in the orphan disease indication Pouchitis. MRM Health leverages its proprietary disruptive CORAL® technology platform to design microbiome-based biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. A significant differentiator is the ability to manufacture these consortia as single drug substance in a single standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.
For more information, please visit the website at www.mrmhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910398074/en/
Contacts
For further information please contact:MRM Health
For further information please contact:MRM Health
Dr Sam Possemiers – CEO
Phone: +32.9.277.08.50
info@mrmhealth.comPrecision AQ (f.k.a. Stern Investor Relations)
Stephanie Ascher
Phone: +1 212-362-1200
Stephanie.ascher@precisionaq.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Announces Proposed Offering of Senior Notes4.11.2025 15:15:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tende
Westlake Announces Cash Tender Offer4.11.2025 15:13:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of a cash tender offer to purchase (the “Offer”) any and all of the outstanding 3.600% Senior Notes due 2026 (the “Notes”) as set forth in the table below. The tender offer is being made solely pursuant to the terms and conditions set forth in an Offer to Purchase, dated November 4, 2025 (the “Offer to Purchase”). Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the tender offer. The tender offer is not conditioned on any minimum amount of the Notes being tendered. Subject to applicable law, Westlake may amend, extend or terminate the tender offer in its sole discretion. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Series of Notes CUSIP Numbers(1) Aggregate Principal Amount Outstanding U.S. Treasury Reference Security(2) Bloomberg Reference Page(2) Fixed Spread(3) 3.600% S
In-House Counsel Warn of Mounting Risks as Service of Process Volume Surges4.11.2025 15:00:00 CET | Press release
93% of in-house counsel say mass arbitration is increasing SOP risk and complexity59% report varying state requirements are driving compliance errors97% use AI for managing or analyzing SOP, yet 96% remain concerned about accuracy and speed The volume of service of process (SOP)—the legal procedure by which one party formally notifies another of a legal action—is surging across the U.S., amplifying operational pressure and compliance risk for in-house legal teams. This is according to a new nationwide study commissioned by CSC, industry-leading registered agent and compliance service provider. CSC surveyed 250 senior in-house counsel across the U.S. and found that rising SOP volume and growing concerns around data accuracy are intensifying both risk and workload pressure.1 Respondents cited data accuracy as a significant challenge to SOP management (61%), followed by rising SOP volume (56%). More than three-quarters (76%) said their departments are spending “too much” or “excessive” ti
Mobile Developers Enter a New Era of Platform Freedom With the Latest Updates to Xsolla Web Shop and Buy Button4.11.2025 15:00:00 CET | Press release
Buy Button For Android In The U.S., Adjustable Daily Rewards, Privacy-Compliant Segmentation, Creator Storefronts, Offerwall, And Extended Coverage Of MMPs to Help Acquire, Engage, And Retain Gamers Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, announces new features and capabilities to the industry-leading web shop solution. Arriving as the U.S. market moves toward a new open era for external payments, new enhancements to the Xsolla Web Shop and Buy Button provide developers with the tools to drive higher margins and more player engagement across iOS and Android. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104283284/en/ (Graphic: Xsolla) The U.S. is now leading the push for more open app ecosystems, with similar moves in the UK, Europe, Japan, Brazil, and beyond to allow external payments. The Xsolla Web Shop enables studios to embrace this shift, increasing
ITRS Named a Visionary in 2025 Gartner® Magic Quadrant™ for Digital Experience Monitoring for Second Consecutive Year4.11.2025 15:00:00 CET | Press release
ITRS today announced it has been named a Visionary in the 2025 Gartner® Magic Quadrant™ for Digital Experience Monitoring (DEM) for the second year in a row. ITRS is a pioneer in real-time monitoring and observability for mission-critical industries. Uptrends, its DEM solution, enables customers to deliver reliable, high-performing digital experiences across regulated and globally distributed environments. “We’re deeply committed to our clients’ success and proud to be named a Visionary for the second year in a row,” commented Ryan Terpstra, CEO of ITRS. “Digital Experience Monitoring connects IT system health to end-user satisfaction — empowering our clients to deliver world-class digital products that build loyalty, strengthen trust, and drive business growth.” Reducing Complexity, Enriching Observability: Agentic AI-Enabled DEM ITRS is infusing agentic AI into its DEM platform to enable customers to deploy holistic monitoring and adapt faster at enterprise scale. This minimizes the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom